Choosing the right patient for 3C Patch®
The 3C Patch® has been extensively studied providing both in vitro and clinical data. The initial primary emphasis has been on developing an evidence base for hard-to-heal diabetic foot ulcers.
The recently published RCT1 for 3C Patch® represents a long-awaited addition to the body of evidence for regenerative medicine.
3C Patch® is cleared by the FDA for the management of exuding wounds, such as leg ulcers, pressure ulcers, and diabetic ulcers and mechanically or surgically debrided wounds.
The product is CE marked in Europe. The intended use of the product is to produce an autologous platelet-rich fibrin for wound management of recalcitrant wounds. 3C Patch® will be the new name for Leucopatch® during 2019.